secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cytek Biosciences, Inc. (CTKB)
CIK:        0001831915
Form:       8-K
Filed at:   2022-03-02T23:59:59+00:00
Accession:  0001193125-22-063025
Event type: other
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Cytek sets 2022 executive comp: salaries, bonuses, equity grants
----------------------------------------------------------------

- CEO Wenbin Jiang: 2022 base salary $545,000, target bonus 80% of base.
- CTO Ming Yan: base $400,000, target bonus 50%; CFO Patrik Jeanmonod: base $385,000, target 50%.
- Equity grants: CEO 163,158 options + 108,137 RSUs; CTO 47,841 options + 31,708 RSUs; CFO 42,310 options + 28,042 RSUs.
- Options exercise price $13.64, vesting over 4 years; RSUs vest quarterly over 4 years.
- 2021 cash bonuses: CEO $163,687, CTO $134,451, CFO $106,492.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1831915/000119312522063025/0001193125-22-063025-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1831915/000119312522063025/d214612d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-063025

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer